These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8572928)

  • 1. Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate.
    Hanton G; Le Net JL; Ruty B; Leblanc B
    Arch Toxicol; 1995; 69(10):698-704. PubMed ID: 8572928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological and immunohistochemical studies on arteritis induced by fenoldopam, a vasodilator, in rats.
    Ikegami H; Shishido T; Ishida K; Hanada T; Nakayama H; Doi K
    Exp Toxicol Pathol; 2001 Apr; 53(1):25-30. PubMed ID: 11370730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA(1) agonists.
    Joseph EC
    Toxicol Lett; 2000 Mar; 112-113():537-46. PubMed ID: 10720777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrastructure of an arterial lesion induced in rats by fenoldopam mesylate, a dopaminergic vasodilator.
    Bugelski PJ; Vockley CM; Sowinski JM; Arena E; Berkowitz BA; Morgan DG
    Br J Exp Pathol; 1989 Apr; 70(2):153-65. PubMed ID: 2567179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.
    Kerns WD; Arena E; Macia RA; Bugelski PJ; Matthews WD; Morgan DG
    Toxicol Pathol; 1989; 17(1 Pt 2):203-13. PubMed ID: 2568682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial medial necrosis and hemorrhage induced in rats by intravenous infusion of fenoldopam mesylate, a dopaminergic vasodilator.
    Yuhas EM; Morgan DG; Arena E; Kupp RP; Saunders LZ; Lewis HB
    Am J Pathol; 1985 Apr; 119(1):83-91. PubMed ID: 2858975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
    Ikegami H; Kajikawa S; Ito K; Nii A; Okamiya H; Nakayama H; Doi K
    Exp Toxicol Pathol; 2002 Jul; 54(1):1-7. PubMed ID: 12180796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.
    Kerns WD; Arena E; Morgan DG
    Am J Pathol; 1989 Aug; 135(2):339-49. PubMed ID: 2571297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of fenoldopam-induced arteritis in rats using
    Fujii Y; Yoshino Y; Chihara K; Nakae A; Enmi JI; Yoshioka Y; Miyawaki I
    Toxicol Rep; 2022; 9():1595-1602. PubMed ID: 36518408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats.
    Newsholme SJ; Thudium DT; Gossett KA; Watson ES; Schwartz LW
    Toxicol Pathol; 2000; 28(5):688-93. PubMed ID: 11026604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: an investigation of morphological, ultrastructural, and hemodynamic changes.
    Joseph EC; Rees JA; Dayan AD
    Toxicol Pathol; 1996; 24(4):436-50. PubMed ID: 8864185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury.
    Brott DA; Richardson RJ; Louden CS
    Toxicol Pathol; 2012 Aug; 40(6):874-86. PubMed ID: 22549976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor.
    Joseph EC; Jones HB; Kerns WD
    Toxicol Pathol; 1996; 24(4):429-35. PubMed ID: 8864184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease.
    Rovella V; Ferrannini M; Tesauro M; Marrone G; Busca A; Sorge R; Manca di Villahermosa S; Casasco M; Di Daniele N; Noce A
    J Nephrol; 2019 Feb; 32(1):75-81. PubMed ID: 29766465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure.
    Aravindan N; Natarajan M; Shaw AD
    J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):179-86. PubMed ID: 16616657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-induced nephropathy: protective role of fenoldopam.
    Caixeta A; Dogan O; Weisz G
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist.
    Albassam MA; Metz AL; Potoczak RE; Gallagher KP; Haleen S; Hallak H; McGuire EJ
    Toxicol Pathol; 2001; 29(3):277-84. PubMed ID: 11442013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153,110) to the rat.
    Westwood FR; Iswaran TJ; Greaves P
    Fundam Appl Toxicol; 1990 May; 14(4):797-809. PubMed ID: 2361578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of
    Fujii Y; Yoshino Y; Chihara K; Nakae A; Enmi JI; Yoshioka Y; Miyawaki I
    Toxicol Rep; 2023; 10():97-103. PubMed ID: 36685272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy.
    Ng MK; Tremmel J; Fitzgerald PJ; Fearon WF
    J Interv Cardiol; 2006 Feb; 19(1):75-9. PubMed ID: 16483344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.